Showing 1 - 9 results of 9 for search 'Nanja van Geel', query time: 0.04s Refine Results
  1. 1
    From IL-17 to IFN-γ in inflammatory skin disorders: Is transdifferentiation a potential treatment target?

    From IL-17 to IFN-γ in inflammatory skin disorders: Is transdifferentiation a potential treatment target? by Arno Belpaire, Nanja van Geel, Reinhart Speeckaert

    Published 2022-07-01
    Get full text
    Article
  2. 2
    The Multifaceted Aspects of Oxidative Stress in the Skin and Other Tissues

    The Multifaceted Aspects of Oxidative Stress in the Skin and Other Tissues by Reinhart Speeckaert, Marijn M. Speeckaert, Nanja van Geel

    Published 2024-09-01
    Get full text
    Article
  3. 3
    The Impact of Antioxidants on Vitiligo and Melasma: A Scoping Review and Meta-Analysis

    The Impact of Antioxidants on Vitiligo and Melasma: A Scoping Review and Meta-Analysis by Reinhart Speeckaert, Vedrana Bulat, Marijn M. Speeckaert, Nanja van Geel

    Published 2023-12-01
    Get full text
    Article
  4. 4
    A meta-analysis of chemokines in vitiligo: Recruiting immune cells towards melanocytes

    A meta-analysis of chemokines in vitiligo: Recruiting immune cells towards melanocytes by Reinhart Speeckaert, Arno Belpaire, Marijn M. Speeckaert, Nanja van Geel

    Published 2023-02-01
    Get full text
    Article
  5. 5
    Autoimmunity in Segmental Vitiligo

    Autoimmunity in Segmental Vitiligo by Reinhart Speeckaert, Jo Lambert, Vedrana Bulat, Arno Belpaire, Marijn Speeckaert, Nanja van Geel

    Published 2020-10-01
    Get full text
    Article
  6. 6
    Patients’ Perception of Vitiligo Severity

    Patients’ Perception of Vitiligo Severity by Nanja van Geel, Charlotte Moock, Marloes Zuidgeest, Sanne Elisabeth Uitentuis, Albert Wolkerstorfer, Reinhart Speeckaert

    Published 2021-06-01
    Get full text
    Article
  7. 7
    Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyResearch in context

    Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyRese... by Thierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, Nanja van Geel, Bethanee J. Schlosser, Xiaoqiang Wu, Xiaohong Huang, Ahmed M. Soliman, David Rosmarin, John E. Harris, Heidi S. Camp, Amit G. Pandya

    Published 2024-07-01
    Get full text
    Article
  8. 8
    Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice

    Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registrie... by Nanja van Geel, Iltefat H. Hamzavi, Amit G. Pandya, Albert Wolkerstorfer, Julien Seneschal, Amit Garg, Phyllis Spuls, Caroline B. Terwee, Sue Mallett, Reinhart Speeckaert, Jean Marie Meurant, Viktoria Eleftheriadou, Khaled Ezzedine

    Published 2022-07-01
    Get full text
    Article
  9. 9
    Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression

    Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression by Ying Jin, Genevieve H. L. Roberts, Tracey M. Ferrara, Songtao Ben, Nanja van Geel, Albert Wolkerstorfer, Khaled Ezzedine, Janet Siebert, Charles P. Neff, Brent E. Palmer, Stephanie A. Santorico, Richard A. Spritz

    Published 2019-01-01
    Get full text
    Article

Search Tools: